Report from the 100th Cardiovascular and Renal Drugs Advisory Committee meeting: US Food and Drug Administration: December 8-9, 2003 Gaithersburg, MD

Circulation. 2004 Jan 20;109(2):e9004-5. doi: 10.1161/01.CIR.0000118364.89571.16.
No abstract available

Publication types

  • Congress
  • News

MeSH terms

  • Acetanilides
  • Angina Pectoris / drug therapy*
  • Aspirin / administration & dosage
  • Aspirin / therapeutic use*
  • Clinical Trials as Topic
  • Delayed-Action Preparations
  • Drug Labeling
  • Humans
  • Maryland
  • Myocardial Infarction / prevention & control*
  • Piperazines / administration & dosage
  • Piperazines / adverse effects
  • Piperazines / therapeutic use*
  • Ranolazine

Substances

  • Acetanilides
  • Delayed-Action Preparations
  • Piperazines
  • Ranolazine
  • Aspirin